Literature DB >> 2891533

Flosequinan as a third agent for the treatment of hypertension: a placebo controlled, double-blind study.

A J Cowley1, R D Wynne, J R Hampton.   

Abstract

The acute and short term antihypertensive effect of flosequinan was determined in 16 hypertensive patients whose blood pressure was inadequately controlled despite treatment with a beta-adrenoceptor blocking agent and a diuretic. Erect and supine systolic and diastolic blood pressure was significantly reduced by flosequinan over the treatment period as compared to placebo. Heart rate was unchanged by flosequinan. Adverse effects were limited to mild headache in 3 patients and taste disturbance in 1 patient, possibly due to salivary excretion of the drug. Flosequinan is a potentially useful vasodilator for the treatment of hypertension.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2891533     DOI: 10.1007/bf00544568

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  2 in total

1.  The pharmacokinetics and haemodynamics of BTS 49 465 and its major metabolite in healthy volunteers.

Authors:  R D Wynne; E L Crampton; I D Hind
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

2.  The effects of BTS 49465 on blood pressure and peripheral arteriolar and venous tone in normal volunteers.

Authors:  A J Cowley; R D Wynne; J R Hampton
Journal:  J Hypertens Suppl       Date:  1984-12
  2 in total
  5 in total

1.  Flosequinan for congestive heart failure: what promise does it hold?

Authors:  J R Hampton
Journal:  Cardiovasc Drugs Ther       Date:  1990-10       Impact factor: 3.727

2.  The effects of flosequinan on regional blood flow in normal man.

Authors:  R A Scott; K L Woods; D B Barnett
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

3.  Flosequinan does not affect systemic and regional vascular responses to simulated orthostatic stress in healthy volunteers.

Authors:  J Duranteau; E Pussard; A Edouard; K Samii; A Berdeaux; J F Giudicelli
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

4.  Flosequinan, a vasodilator with a novel mechanism of action.

Authors:  M S Resnick; L A Maitland; K G Morgan
Journal:  Br J Pharmacol       Date:  1991-04       Impact factor: 8.739

5.  Lack of pharmacodynamic interactions between acute dose flosequinan and xamoterol. A pilot study in healthy subjects.

Authors:  H W Ng; T J Walley; Y Tsao; A M Breckenridge
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.